LGC Genomics appointed Bio-Mediator as a distributor for Finland and the Baltic states
LGC provides an array of flexible nucleic acid sample extraction, DNA sequencing, next generation sequencing and genotyping products and services to pharmaceutical and biotechnology companies, private and public research organisations. Read more at www.lgcgroup.com
“Bio-Mediator is very excited about the possibility to offer these high quality products and services and it broadens our product portfolio significantly”, Pauli Lindberg, CEO of the company says.
James Heseltine, Head of Business Development, Genomics, LGC, said, “We are excited to be working with Bio-Mediator, enhancing LGC’s strong position within the life science and agricultural biotechnology sectors. Through this new agreement, Bio-Mediator will leverage highly complementary product lines within DNA Extraction, Genotyping & Sequencing markets”.
LGC scientists have contributed significantly to the development of new genotyping technologies, making affordable projects accessible to a broad range of customers, independent of project size. To date, they have extracted DNA from more than 10 million samples, as well as having processed more than one billion PCR reactions.
On the picture: James Heseltine, Head of Business Development at LGC Genomics (left) and Pauli Lindberg, CEO of Bio-Mediator
29 June 2018
Brokerage Event for 2019 SC1 calls (Oslo)
21 June 2018
Bone Innovation Summit (Lübeck)